Thermopylae Holdings Ltd. bought 60,565 shares of AbCellera Biologics Inc. at $11.54 for $699k on Nov 12, 2026

Buy
Form 4 code P. Open-market or private purchase of a non-derivative or derivative security.
10% owner
10%
Filed Nov 12, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$698,920.10Shares × reported price
Shares traded
60,565Common Shares
Price per share
$11.54Reported price. Read footnotes for ranges.
% of reported position traded
0.11%This security and ownership context
Holdings after
56,194,662Direct
Trade date
Nov 12, 2026Buy
Filed
Nov 12, 2026, 1:15 PM ET0-day reporting delay
Accession
0001834449-26-000009Code P · Transaction 398543
How reported position traded is calculated

Shares purchased ÷ (holdings after − shares purchased). Estimated position before: 56,134,097 shares.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

No other transaction rows in this filing.

1 transaction row in this filing. Joint filers share the same rows.

ABCL price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ABCL · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago 0%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The price reported in Column 4 is a weighted-average price. These shares were acquired in multiple transactions at prices ranging from $11.29 to $11.86. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares acquired at each separate price within the range set forth in this footnote.